ARID1A and pancreatic ductal adenocarcinoma: ARID1A is mutated in 10% of intraductal papillary mucinous neoplasms (IPMNs) [101] and 6% of pancreatic adenocarcinoma (PDAC) [102], while KRAS mutations are found in more than 95% of pancreatic ductal adenocarcinoma (PDAC) [102].